#USA #Irvine #Prix Galien #ENDO-205 #EndoCyclic Therapeutics

EndoCyclic Therapeutics Nominated for the 2026 Prix Galien USA Award

EndoCyclic Therapeutics, Inc., a prominent player in the biopharmaceutical industry, has officially been nominated for the 2026 Prix Galien USA Award in the category of Best Startup. This accolade recognizes the company's groundbreaking contributions to developing non-hormonal peptide therapeutics and diagnostics aimed at transforming the landscape of endometriosis care.

A Significant Recognition

The Prix Galien is widely considered the highest honor in biomedical research, akin to the Nobel Prize. The nominations are determined by a distinguished committee composed of thought leaders in biomedical science, medicine, and industry, including Nobel Prize winners and senior executives from world-renowned biopharmaceutical firms. The committee is chaired by Kenneth C. Frazier, the former Chairman and CEO of Merck & Co., Inc.

EndoCyclic's nomination follows crucial advancements, particularly the FDA's recent clearance of the Investigational New Drug (IND) application for ENDO-205. This innovative therapy is designed to specifically target and eliminate endometriosis lesions rather than merely alleviating symptoms. This recognition underscores the company’s revolutionary precision peptide platform alongside its non-invasive diagnostic program, FemLUNA™, which seeks to redefine the detection and management of endometriosis.

Addressing a Major Health Issue

Dr. Tanya Petrossian, the founder and CEO of EndoCyclic, expressed her gratitude for the nomination, highlighting the profound impact their technology can have on women’s health. For years, women suffering from endometriosis have endured a relentless cycle of late diagnoses, chronic pain, hormonal treatments, and invasive surgeries with little resolution.

Dr. Petrossian noted, “EndoCyclic’s innovation goes beyond just a new peptide or mechanism of action; it represents a visionary approach to endometriosis care that empowers women.”

About EndoCyclic Therapeutics

Founded with a focus on developing cutting-edge therapeutics and diagnostics, EndoCyclic Therapeutics aims to address complex health issues that have long been neglected, particularly in women's health and oncology. Utilizing a proprietary precision peptide platform, EndoCyclic is advancing a portfolio of targeted therapies designed to tackle significant challenges in disease detection and patient treatment.

The lead program, ENDO-205, stands out as the first non-hormonal therapy aimed at selectively targeting the lesions associated with endometriosis, allowing for a treatment approach that avoids hormone manipulation and reduces the need for surgical interventions. In conjunction with ENDO-205, the FemLUNA™ imaging agent aims to facilitate accurate, non-invasive endometriosis detection, potentially offering a much-needed alternative to the invasive laparoscopy, traditionally regarded as the gold standard for diagnosis.

The company is further expanding its precision peptide platform into other areas within women’s health and oncology, aiming to create targeted therapeutic and diagnostic solutions for diseases with significant unmet needs.

The Galien Foundation's Role

The Prix Galien USA, managed by the Galien Foundation, celebrates excellence in scientific innovation that enhances human health. The Foundation aims to be a catalyst for the next generation of innovative treatments and technologies that could redefine medical practice and save lives. First established in 1970, the Prix Galien has gained global recognition for promoting progress through the development of innovative medicines worldwide.

For more information about EndoCyclic Therapeutics and its innovative solutions, visit www.endocyclictherapeutics.com.